Skip to main navigation
  • >Newsroom
    • Latest News
    • Archives
    • Media Inquiries
  • >Careers
    • Join Us
  • >Contact
    • General Inquiries
Search
Twitter LinkedIn
NexImmune, Inc. NexImmune, Inc.
  • Our Technology
    • Our Technology
      • AIM™ Nanoparticle Platform
      • AIM™ ACT Adoptive Cell Therapy
      • AIM™ INJ Direct Injection
      • Abstracts and Publications
    • Our Pipeline
      • Overview
    • Our Company
      • Overview
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
    • Investors
      • Overview
      • Press Releases
      • Events and Presentations
      • Financials and Filings
      • Analyst Coverage
      • Stock Information
      • Corporate Governance
      • Email Alerts
      • Contact
  • Our Pipeline
    • Our Technology
      • AIM™ Nanoparticle Platform
      • AIM™ ACT Adoptive Cell Therapy
      • AIM™ INJ Direct Injection
      • Abstracts and Publications
    • Our Pipeline
      • Overview
    • Our Company
      • Overview
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
    • Investors
      • Overview
      • Press Releases
      • Events and Presentations
      • Financials and Filings
      • Analyst Coverage
      • Stock Information
      • Corporate Governance
      • Email Alerts
      • Contact
  • Our Company
    • Our Technology
      • AIM™ Nanoparticle Platform
      • AIM™ ACT Adoptive Cell Therapy
      • AIM™ INJ Direct Injection
      • Abstracts and Publications
    • Our Pipeline
      • Overview
    • Our Company
      • Overview
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
    • Investors
      • Overview
      • Press Releases
      • Events and Presentations
      • Financials and Filings
      • Analyst Coverage
      • Stock Information
      • Corporate Governance
      • Email Alerts
      • Contact
  • Investors
    • Our Technology
      • AIM™ Nanoparticle Platform
      • AIM™ ACT Adoptive Cell Therapy
      • AIM™ INJ Direct Injection
      • Abstracts and Publications
    • Our Pipeline
      • Overview
    • Our Company
      • Overview
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
    • Investors
      • Overview
      • Press Releases
      • Events and Presentations
      • Financials and Filings
      • Analyst Coverage
      • Stock Information
      • Corporate Governance
      • Email Alerts
      • Contact
  • Our Technology
    • AIM™ Nanoparticle Platform
    • AIM™ ACT Adoptive Cell Therapy
    • AIM™ INJ Direct Injection
    • Abstracts and Publications
  • Our Pipeline
    • Overview
  • Our Company
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Analyst Coverage
    • Stock Information
    • Corporate Governance
    • Email Alerts
    • Contact
  • Newsroom
    • Latest News
    • Archives
    • Media Inquiries
  • Careers
    • Join Us
  • Contact
    • General Inquiries

Investors: Event

Barclays Global Healthcare Conference 2021

March 11, 2021 at 10:55 AM EST

Listen to webcast
  • Overview
  • Press Releases
  • Events and Presentations
  • Financials and Filings
  • Analyst Coverage
  • Stock Information
  • Corporate Governance
  • Email Alerts
  • Contact
  • Our Technology
  • AIM™ Nanoparticle Platform
  • AIM™ ACT Adoptive Cell Therapy
  • AIM™ INJ Direct Injection
  • Abstracts and Publications
  • Our Pipeline
  • Overview
  • Careers
  • Join Us
  • Our Company
  • Overview
  • Leadership
  • Board of Directors
  • Scientific Advisory Board
  • Newsroom
  • Latest News
  • Archives
  • Media Inquiries
  • Contact
  • General Inquiries
  • Investors
  • Overview
  • Press Releases
  • Events and Presentations
  • Financials and Filings
  • Analyst Coverage
  • Stock Information
  • Corporate Governance
  • Email Alerts
  • Contact
About Us

NexImmune is a rapidly growing leader in the emerging field of antigen-directed immunotherapies. We are developing a novel technology platform with broad application across multiple disease areas.

Our Vision is to conquer cancer and life-threatening immune-mediated conditions by directing natural, disease-specific immune responses.

NexImmune, Inc. footer logo

9119 Gaither Road
Gaithersburg, MD 20877

Twitter LinkedIn

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to NexImmune, its subsidiaries or affiliates. No use of any NexImmune trademark, trade name, or trade dress in this site may be made without the prior written authorization of NexImmune, except to identify the product or services of the company.

© NexImmune, Inc.. All Rights Reserved. 2021

  • Terms of Use
  • Privacy
  • Cookies